



(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
03.09.2003 Bulletin 2003/36

(51) Int Cl.7: **C12N 15/19, C07K 14/475,
A61K 38/12**

(21) Application number: **95942271.8**

(86) International application number:
PCT/JP95/02708

(22) Date of filing: **27.12.1995**

(87) International publication number:
WO 96/020214 (04.07.1996 Gazette 1996/30)

(54) **TCF MUTANT**

TCF MUTANTE

MUTANT DE TCF

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB IE IT LI LU NL SE

• **YAMASHITA, Yasushi**
Shimotsuga-gun, Tochigi 329-05 (JP)

(30) Priority: **27.12.1994 JP 33788594**

(74) Representative: **Wakerley, Helen Rachael**
Reddie & Grose,
16 Theobalds Road
London WC1X 8PL (GB)

(43) Date of publication of application:
12.02.1997 Bulletin 1997/07

(60) Divisional application:
02077639.9 / 1 275 718

(56) References cited:
WO-A-90/10651 WO-A-93/23541

(73) Proprietor: **DAIICHI PHARMACEUTICAL CO., LTD.**
Chuo-ku, Tokyo 103-8234 (JP)

(72) Inventors:

- **KINOSAKI, Masahiko**
Shimotsuga-gun, Tochigi 329-05 (JP)
- **YAMAGUCHI, Kyoji**
Oomiya-shi, Saitama 330 (JP)
- **KOBAYASHI, Fumie**
Kawachi-gun, Tochigi 329-11 (JP)
- **GOTO, Masaaki**
Shimotsuga-gun, Tochigi 329-05 (JP)
- **MURAKAMI, Akihiko**
Shimotsuga-gun, Tochigi 321-02 (JP)
- **UEDA, Masatsugu**
Kawagoe-shi, Saitama 350-11 (JP)
- **HIGASHIO, Kanji**
Kawagoe-shi, Saitama 350 (JP)

- **MIZUNO K. ET AL.:** "Hairpin loop and second Kringle domain are essential sites for heparin binding and biological activity of Hepatocyte Growth Factor" J. BIOL. CHEM., vol. 269, no. 14, 14 January 1994, pages 1131-1136, XP002074886
- **NUCLEIC ACIDS RES.**, Vol. 10, No. 20, 1982, M.J. ZOLLER et al., "Oligonucleotide-Directed Mutagenesis Using M13-Derived Vectors", p. 6487-6500.
- **BIOCHEMISTRY**, Vol. 31, No. 4, 1992, J. LAWLER et al., "Expression and Mutagenesis of Thrombospondin", p. 1173-1180.
- **EUR. J. HAEMATOL.**, Vol. 47, No. 5, 1991, M. DONNER et al., "An Arginine-545-Cysteine-545 Substitution Mutation of the Von Willebrand Factor in Type IIB Von Willebrand's Disease", p. 342-345.

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).